Vitrectomy after ocriplasmin for VVMT adhesion of MH study
Reviewed by Jonathan Chan

This is a multicentre retrospective study of 51 eyes that received intravitreal ocriplasmin between January 2013 to January 2014 for symptomatic vitreomacular (VMT) +/- macular hole (MH), and then went on to PPV for persistent pathology, comparing a control group of 22 eyes which preceded directly to PPV. VA was better at all time points in the PPV only group compared to the Ocriplasmin-treated group, at three and six months after PPV. Both groups had similar amount of visual improvement. Both groups had similar rates of apthology resolution; 50/51 (98%) eyes in the ocriplasmin group and 22/22 (100%) in the PPV only group had release of VMT and / or MH closure after PPV. Similar rates of PPV related complications were noted in both groups. The authors mentioned the retrospective nature, small size sample, limited follow-up duration, differences in baseline features between the groups, and phakic eyes were not excluded in the study.

Vitrectomy after ocriplasmin for vitreomacular adhesion or macular hole study.
Greven MA, Garg S, Chiu B, et al.
BRITISH JOURNAL OF OPHTHALMOLOGY
2016;100:1211-5.